(UroToday.com) The 2024 European Association of Urology (EAU) annual congress held in Paris, France between April 5th and 8th was host to a joint session of the EAU and the Advanced Prostate Cancer Consensus (APCCC). Professor Nick James discussed the optimal treatment in the case of PSA persistence following radical prostatectomy.
(UroToday.com) The 2024 European Association of Urology (EAU) annual congress held in Paris, France between April 5th and 8th was host to a joint session of the EAU and the Advanced Prostate Cancer Consensus (APCCC). Dr. Derya Tilki discussed whether all PSA persistence is created equal, and what definition/diagnostic work-up should be accordingly used.
(UroToday.com) The 2024 European Association of Urology (EAU) annual congress held in Paris, France between April 5th and 8th was host to a joint session of the EAU and the Advanced Prostate Cancer Consensus (APCCC). Professor Aurelius Omlin discussed what to test for prior to the start of hormonal treatment and what to monitor for thereafter.
(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a plenary session on personalized approaches in high-risk and metastatic prostate cancer, and a presentation by Dr. Antti Rannikko discussing systemic therapy alone for patients with high-risk biochemical recurrence after radical prostatectomy and negative PSMA PET.
(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a session on metastatic urothelial cancer, and a presentation by Dr. Thomas Büttner discussing membranous NECTIN-4 expression in metastasis compared to the primary tumor and the outcome of enfortumab vedotin response. Among patients with metastatic urothelial carcinoma, there is a previously uncharacterized subgroup with primary resistance to therapy with enfortumab vedotin. As such, the membranous expression of the enfortumab vedotin target NECTIN-4 expression within the tumor tissue seems to be involved. The objective of this study presented at EAU 2024 was to investigate whether an analysis of the primary tumor is representative of metastatic disease, comparing the predictive value of membranous NECTIN-4 expression in the primary tumor tissue with that of a metastatic urothelial carcinoma distant metastasis sample.
(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a plenary session on personalized approaches in high-risk and metastatic prostate cancer, and a presentation by Dr. Derya Tilki discussing the guideline’s view for patients with high-risk biochemical recurrence after radical prostatectomy and negative PSMA PET. Dr. Tilki started by highlighting the background notes from the EAU guidelines, specifically “between 27% and 53% of all patients undergoing radical prostatectomy or radiotherapy develop a rising PSA (PSA recurrence). While metastatic progression is universally preceded by rising PSA levels, physicians must inform the patient that the natural history of PSA-only recurrence may be prolonged and that a measurable PSA may not necessarily lead to clinically apparent metastatic disease.”
(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a session on metastatic urothelial cancer, and a presentation by Dr. Peter Goebell discussing preliminary results of the prospective CARAT-UBC registry assessing first-line maintenance therapy in patients with locally advanced or metastatic urothelial carcinoma in routine care in Germany.
(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a plenary session on personalized approaches in high-risk and metastatic prostate cancer, and a state of the art lecture by Dr. Alberto Bossi discussing who benefits from local therapy in metastatic hormone sensitive prostate cancer (mHSPC). Dr. Bossi emphasized that the EAU guidelines for the first-line treatment of hormone sensitive metastatic disease state that we should “offer ADT combined with prostate radiotherapy (using up to the equivalent of 72 Gy in 2 Gy fractions) to patients whose first presentation is M1 disease and who have low volume of disease by the CHAARTED criteria” (Strength rating: Strong). Moreover, “do not offer ADT combined with surgery to M1 patients outside of clinical trials” (Strength rating: Strong), and “only offer metastasis directed therapy to M1 patients within a clinical trial setting or a well-designed prospective cohort study” (Strength rating: Strong).
(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a plenary session on living with advanced kidney cancer and urothelial cancer, and a presentation by Dr. Laurence Albiges discussing that for first line metastatic kidney cancer, we should be using triplet combinations at any cost.
(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a session on metastatic urothelial cancer, and a trial in progress presentation by Dr. Thomas Powles discussing DV-001, a phase 3 trial of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2. Platinum-based chemotherapy has been the standard first-line therapy for locally advanced/metastatic urothelial carcinoma, which is an aggressive disease. Recently, enfortumab vedotin, a nectin-4-directed antibody drug conjugate with a MMAE payload, + pembrolizumab has shown improved outcomes over chemotherapy.1 HER2 expression (defined as IHC >= 1+) has been reported in approximately half of all patients across multiple tumor types, including urothelial carcinoma, and may be associated with poor outcomes. Disitamab vedotin is an investigational antibody-drug conjugate comprising a fully humanized HER2-directed monoclonal antibody, disitamab, conjugated to MMAE via protease-cleavable mc-vc linker:
(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a plenary session on living with advanced kidney cancer and urothelial cancer, and a presentation by Dr. Sarah Psutka discussing that for first line metastatic kidney cancer less is more.
(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a plenary session on personalized approaches in high-risk and metastatic prostate cancer, and a presentation by Dr. Declan Murphy discussing that when a PSMA PET is negative for high risk disease, we can skip the extended pelvic lymph node dissection.
(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a session on navigating urothelial carcinoma from innovative diagnostics to therapeutic strategies, and a presentation by Dr. Borivoj Golijanin discussing pembrolizumab in BCG refractory non-muscle invasive bladder cancer and the association of adverse events with discontinuation of treatment.
(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a plenary session on personalized approaches in high-risk and metastatic prostate cancer, and a state of the art lecture by Dr. Roderick Van Den Bergh discussing clinical and molecular stratification of men with biochemical recurrence after radical prostatectomy. Dr. Van Den Bergh notes that biochemical recurrence is a very heterogeneous disease space:
(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a plenary session on personalized approaches in high-risk and metastatic prostate cancer, and a presentation by Dr. Alexandre De La Taille discussing that when a PSMA PET is negative for high risk disease, we cannot skip the extended pelvic lymph node dissection.
(UroToday.com) The 2024 European Association of Urology (EAU) annual congress held in Paris, France between April 5th and 8th was host to a game changing session addressing the role of lymph node dissection in prostate cancer. Dr. Karim Touijer presented an update on the limited versus extended lymph node dissection randomized clinical trial.
(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a plenary session on personalized approaches in high-risk and metastatic prostate cancer, and a state of the art lecture by Dr. Karim Fizazi discussing how to personalize treatment in metastatic hormone sensitive prostate cancer (mHSPC). Dr. Fizazi started by emphasizing that yes, of course, the number of bone metastases has prognostic value. But, does counting bone metastases help with treatment decision making? Before 2023, common thoughts were that for low volume mHSPC there would be no use of docetaxel, utilization of ARPIs, and radiotherapy to the primary. For high volume mHSPC, patients would receive triplet systemic therapy (ADT + docetaxel + ARPI), with no radiotherapy to the primary tumor. Based on volume data from CHAARTED1 and STAMPEDE,2 there was clinical benefit to using docetaxel in high volume disease, however, in low volume disease there was a benefit in the STAMPEDE population but not in the CHAARTED cohort:
(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a plenary session on living with advanced kidney cancer and urothelial cancer, and a state of the art lecture by Dr. Andrea Necchi discussing whether there is a new standard treatment of metastatic bladder cancer based on EV-302/KEYNOTE-A39. Dr. Necchi started his presentation by highlighting the first-line therapy for metastatic urothelial carcinoma prior to the ESMO 2023 meeting, emphasizing both negative and positive trials in this disease space:
(UroToday.com) The 2024 European Association of Urology (EAU) annual congress held in Paris, France between April 5th and 8th was host to a joint session of the EAU and the Advanced Prostate Cancer Consensus (APCCC). Professor Elena Castro discussed whether germline genetic testing is necessary and/or helpful for the management of patients with synchronous metastatic hormone-sensitive prostate cancer (mHSPC).
(UroToday.com) The 2024 European Association of Urology (EAU) annual congress held in Paris, France was host to a joint session of the EAU and the Advanced Prostate Cancer Consensus (APCCC). Professor Nicola Fossati discussed the current evidence for surgery in the treatment of patients with synchronous metastatic hormone-sensitive prostate cancer (mHSPC).
